Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for OptimizeRx (OPRX) over the last 8 years, with Q3 2025 value amounting to $4.5 million.

  • OptimizeRx's Non-Current Deferred Tax Liability rose 6559.73% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 6559.73%. This contributed to the annual value of $4.5 million for FY2024, which is 355.08% up from last year.
  • OptimizeRx's Non-Current Deferred Tax Liability amounted to $4.5 million in Q3 2025, which was up 6559.73% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Non-Current Deferred Tax Liability ranged from a high of $4.5 million in Q4 2024 and a low of $2.3 million during Q4 2022
  • Its 5-year average for Non-Current Deferred Tax Liability is $3.7 million, with a median of $4.1 million in 2023.
  • As far as peak fluctuations go, OptimizeRx's Non-Current Deferred Tax Liability soared by 8613.73% in 2023, and later crashed by 2026.75% in 2025.
  • OptimizeRx's Non-Current Deferred Tax Liability (Quarter) stood at $2.6 million in 2021, then decreased by 11.07% to $2.3 million in 2022, then soared by 86.14% to $4.3 million in 2023, then grew by 3.55% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $3.5 million for Q2 2025, and $3.8 million during Q1 2025.